Duchenne, Solid Biosciences and gene therapy

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came out resulting in this massive single-day rise?
Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation,
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.
Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has surged back into the Duchenne muscular dystrophy gene therapy race. The biotech reported expectation-busting phase 1 data on its next-generation candidate,
Solid Biosciences surges on Duchenne therapy success
Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic medicines for neuromuscular and cardiac diseases company announced positive initial data from the Phase I/II INSPIRE DUCHENNE trial evaluating SGT-003.
Solid Biosciences Shares Rise After Positive Trial Data for SGT-003 in Duchenne MD
Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Solid Bio surges after trial data for lead asset in Duchenne
Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported promising early results from a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy,
Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $16.00
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Solid Biosciences Announces Pricing of Underwritten Offering
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
Solid Biosciences price target raised to $16 from $15 at Chardan
Chardan raised the firm’s price target on Solid Biosciences (SLDB) to $16 from $15 and keeps a Buy rating on the shares. The company has ...